{"entity":{"id":"nct07096778","kind":"trial","name":"Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of Inobrodib run by CellCentric Ltd., now recruiting.","summary":"Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07096778 by CellCentric Ltd., with 100 participants planned, started 2026-01-22, primary completion expected 2029-12-01. Conditions recorded: Multiple Myeloma Refractory, Multiple Myeloma in Relapse. Interventions recorded: Inobrodib, Pomalidomide, Dexamethasone.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07096778","url":"https://clinicaltrials.gov/study/NCT07096778"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["inobrodib"],"companies":["cellcentric"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07096778","phase":"2","setting":"A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","sponsor":"CellCentric Ltd.","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07096778/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"inobrodib","kind":"drug","name":"Inobrodib","route":"/drugs/inobrodib/"}],"company":[{"id":"cellcentric","kind":"company","name":"CellCentric","route":"/companies/cellcentric/"}]}}